Keryx Biopharma (KERX) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-127.31M
Stock compensation expense	10.56M
Depreciation and amortization
Loss on sale of available-for-sale securities
Impairment of investment securities
(Increase) decrease in other current assets	-563K
(Increase) decrease in accrued interest receivable	0
Increase in security deposits
(Increase) decrease in other assets
Increase in accounts payable and accrued expenses	-2.76M
Decrease in accrued compensation and related liabilities	-550K
Decrease in other liabilities	105K
Net cash used in operating activities
Purchases of property, plant and equipment	-2.06M
Investment in held-to-maturity short-term securities
Proceeds from maturity of held-to-maturity short-term securities	0
Proceeds from sale of available-for-sale long-term securities
Net cash (used in) provided by investing activities
Proceeds from public offering, net	0
Proceeds from exercise of warrants from public offering, net
Proceeds from exercise of options	198K
Net cash provided by financing activities
NET INCREASE IN CASH AND CASH EQUIVALENTS	-68.12M
Cash and cash equivalents at beginning of period	200.29M
CASH AND CASH EQUIVALENTS AT END OF PERIOD	132.17M

Entities mentioned with KERX

View All Entities